Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus MYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus MYCHEL.
COR-OTICIN vs MYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
1-2 drops in each affected ear twice daily for 7 days.
Adults: 200 mg orally twice daily for 14 days.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic